立体定向体部放疗联合雄激素剥夺治疗前列腺癌寡转移的II期试验(SBRT-SG 05)
这项前瞻性多中心II期试验纳入81例寡复发前列腺癌患者(激素敏感主队列和去势抵抗探索队列),给予ADT联合SBRT至少24个月。中位随访40个月,主队列3年局部无复发生存率92.5%,探索队列85.7%;未发生≥III级毒性,仅2例(2.4%)出现II级毒性。结论认为联合治疗安全且临床结局良好,去势抵抗患者需验证研究。
要点
- 主队列3年局部无复发生存率92.5%,探索队列85.7%。
- 主队列3年生化无复发生存率50.6%,转移无进展生存率67%。
- 未发生≥III级毒性,仅2例(2.4%)出现II级毒性。
核心结论
- SBRT联合ADT在激素敏感和去势抵抗前列腺癌患者中安全且显示良好临床结局。
- 作者认为去势抵抗前列腺癌患者需要验证研究。
研究设计与样本
- 前瞻性多中心II期试验(SBRT-SG 05,NCT02192788),由SBRT-SG、Grupo de Investigación Clínica en Oncología Radioterápica和Sociedad Española de Oncología Radioterápica协作开展。
- 纳入2014年至2019年14个中心的81例寡复发前列腺癌患者,共126个病灶,其中14例为去势抵抗。
- 激素敏感主队列和去势抵抗探索队列均接受ADT联合SBRT,自入组起至少24个月;不允许同期化疗、阿比特龙或恩扎卢胺。
主要发现
- 中位随访40个月(范围12-58个月),主队列3年局部无复发生存率92.5%(95%CI 79.9%-96.3%),探索队列85.7%(95%CI 48.2%-95.6%)。
- 主队列1、2、3年生化无复发生存率分别为91%(95%CI 81%-95.8%)、73.7%(95%CI 61.1%-82.8%)、50.6%(95%CI 36.2%-63.3%)。
- 主队列1、2、3年转移无进展生存率分别为92%(95%CI 83%-97%)、81%(95%CI 70%-89%)、67%(95%CI 53%-77%)。
- 探索队列1、2、3年转移无进展生存率分别为64%(95%CI 34%-83%)、43%(95%CI 18%-66%)、26%(95%CI 7%-51%)。
- 无患者发生III级或以上毒性或与局部进展相关的症状,仅2例(2.4%)发生II级毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为去势抵抗前列腺癌患者需要验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: SBRT-Spanish Group-05 (ClinicalTrials.gov.Identifier: NCT02192788) is a collaborative (SBRT-SG, Grupo de Investigación Clínica en Oncología Radioterápica, and Sociedad Española de Oncología Radioterápica) prospective multicenter phase II trial testing stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT) in patients with oligorecurrent prostate cancer. METHODS AND MATERIALS: Two cohorts of patients with prostate cancer in an oligorecurrent stage (hormone-sensitive in the principal cohort and castration-resistant in the exploratory cohort) were assigned to receive ADT and SBRT for at least 24 months from the time of the enrollment. Concomitant treatment with chemotherapy, abiraterone, or enzalutamide was not allowed. Oncologic outcomes were assessed in both cohorts. Toxicity was prospectively analyzed. RESULTS: From 2014 to 2019, 81 patients with a total of 126 lesions from 14 centers met the inclusion criteria, 14 of whom were castration-resistant. With a median follow-up of 40 months (12-58 months), 3-year local recurrence-free survival was 92.5% (95% CI, 79.9%-96.3%) and 85.7% (95% CI, 48.2%-95.6%) in the principal and exploratory cohorts, respectively. In the principal cohort, biochemical relapse-free survival and metastasis progression-free survival at 1, 2, and 3 years were 91% (95% CI, 81%-95.8%), 73.7% (95% CI, 61.1%-82.8%), 50.6% (95% CI, 36.2%-63.3%), and 92% (95% CI, 83%-97%), 81% (95% CI, 70%-89%), and 67% (95% CI, 53%-77%), respectively. In the exploratory cohort, metastasis progression-free survival at 1, 2, and 3 years was 64% (95% CI, 34%-83%), 43% (95% CI, 18%-66%), and 26% (95% CI, 7%-51%), respectively. None of the patients developed grade III or higher toxicity or symptoms related to local progression, and only 2 (2.4%) patients developed grade II toxicity. CONCLUSIONS: The combination of SBRT and ADT is safe and shows favorable clinical outcomes in patients with hormone-sensitive and castration-resistant prostate cancer. Validation studies are needed in patients with castration-resistant prostate cancer.
引用
- Conde-Moreno AJ, López-Campos F, Hervás A, et al. A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05). Pract Radiat Oncol. 2024. PMID: 38944806. doi:10.1016/j.prro.2024.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。